Managed Care Industry Investor Overview: UnitedHealth, Humana, MLR, Medicare Advantage

The medical loss ratio (MLR) is the percentage of premium revenue that a managed care organization pays out as medical claims. It is calculated as: medical costs paid to providers divided by premium revenue collected from members (or their employers and government payers). An MLR of 85% means the company pays $0.85 in claims for every $1.00 it collects in premiums, retaining $0.15 to cover administrative expenses and profit. The MLR is the single most important financial metric for managed care companies because it directly measures the gap between the premium price set in advance (based on actuarial predictions of future medical utilization) and the actual medical costs experienced by the enrolled population. When actual utilization is lower than predicted -- members stay healthier than expected, use fewer emergency services, defer elective procedures -- the MLR improves and profit expands. When actual utilization is higher than predicted -- a flu season is worse than normal, a new expensive cancer treatment becomes standard of care, behavioral health admissions surge -- the MLR deteriorates and profit compresses. The ACA mandates minimum MLR floors to protect consumers: individual and small-group insurers must spend at least 80% of premiums on medical care; large-group insurers must spend at least 85%. If an insurer's MLR falls below the floor, it must rebate the difference to members. This ACA rule effectively caps profitability at the top of the premium range (you cannot keep more than 15-20% of premiums as non-medical costs regardless of how low costs are) while leaving MCOs to compete by managing costs as efficiently as possible below the cap. The best-managed MCOs (historically UnitedHealth, Cigna, and Anthem) achieved MLRs of 82-84%, retaining 16-18% for SG&A and profit. The most challenged MCOs -- particularly in Medicare Advantage following the 2022-2024 medical cost inflation -- saw MLRs rise above 90%, consuming nearly all available margin for operating expenses.

The 2022-2024 Medicare Advantage margin deterioration was driven by the collision of several simultaneous adverse trends that MCOs' actuarial models failed to adequately predict, causing the worst medical cost surprise in the industry's recent history. First, post-COVID deferred care utilization surged. During COVID lockdowns (2020-2021), Medicare beneficiaries deferred elective procedures, non-urgent specialist visits, and routine screenings at an unprecedented scale. Beginning in 2022 and accelerating through 2023-2024, this deferred care demand returned -- but the patients who had deferred care for 2-3 years were now presenting with more advanced disease stages, requiring more complex and expensive treatments than if they had sought care earlier. An early-stage cancer patient who delayed diagnosis by 18 months now presents with late-stage disease requiring surgery, chemotherapy, and radiation rather than a targeted therapy; a deferred joint replacement that became a more complex total joint replacement; a managed cardiovascular condition that progressed to a cardiac intervention. The complexity shift toward higher-acuity procedures materially elevated average cost per encounter beyond what 2022-2023 actuarial models anticipated. Second, behavioral health utilization surged beyond historical patterns. Mental health, substance abuse, and psychiatric hospitalization rates increased substantially post-COVID, driven by epidemic-level anxiety, depression, and substance use disorder exacerbated by pandemic isolation, economic stress, and social disruption. Behavioral health is expensive (inpatient psychiatric stays, intensive outpatient programs) and difficult to manage through traditional utilization management tools used for medical/surgical care. Third, site-of-care shifts elevated costs. More procedures migrated from lower-cost outpatient ambulatory surgery centers to higher-cost hospital outpatient departments, partly because hospital systems acquired physician practices and independent surgery centers, billing the same procedures at facility rates. These three factors collectively drove 2022-2024 MLR deterioration of 200-400 basis points in Medicare Advantage for most large insurers, causing significant earnings misses and stock declines (Humana -50% peak-to-trough). The recovery requires CMS to grant higher benchmark rate adjustments (which lag actual cost experience by 2 years), MCOs to reprice their MA plans with higher premiums, and utilization management programs to adapt to the new demand patterns.

UnitedHealth Group has evolved from a traditional health insurer into a vertically integrated healthcare services company, with its Optum business unit generating more operating income than UnitedHealthcare insurance by 2023. This transformation distinguishes UnitedHealth structurally from peers like Humana (still primarily an insurer) or Centene (primarily government program managed care). The key distinction is the ownership of the healthcare delivery and services infrastructure that other insurers pay external parties to provide. UnitedHealthcare insurance collects premiums and pays medical claims, as all MCOs do. Optum owns and operates a network of physician practices (OptumHealth manages over 90,000 employed and affiliated physicians in primary care, specialty care, and urgent care across the U.S.), pharmacy benefit management (OptumRx processes over 1.5 billion prescriptions annually through its PBM platform), and health IT and analytics (OptumInsight provides revenue cycle management, clinical analytics, and health IT services to hospitals, health systems, and payers). The vertical integration strategy creates three potential advantages: captured care management (UnitedHealthcare members who receive primary care from Optum physicians are managed more intensively for chronic disease and preventive care, theoretically reducing hospitalizations and emergency visits); captured pharmacy economics (OptumRx managing UnitedHealthcare members' pharmacy benefits allows UnitedHealth to capture the pharmacy gross margin that would otherwise flow to an external PBM like CVS Caremark or Express Scripts); and data advantages (Optum's analytics platform uses integrated claims, pharmacy, and clinical data across UnitedHealth's membership to identify high-risk patients earlier and intervene more cost-effectively than competitors using fragmented data sources). The strategic and financial logic of this integration is UnitedHealth's central thesis for 10-15% annual EPS growth in a sector where most peers target 8-12%. The countervailing risk is regulatory: the DOJ has investigated UnitedHealth's acquisitions (particularly its attempted $13 billion acquisition of Change Healthcare, which processes a significant share of all U.S. healthcare transactions) for anticompetitive effects, and growing scrutiny of health insurer vertical integration could constrain future acquisition-driven integration.

The Medicaid redetermination cycle refers to the periodic process by which state Medicaid agencies verify that enrolled members still meet the income and household eligibility requirements to receive Medicaid benefits. Under normal circumstances, states conduct annual eligibility redeterminations and remove members who no longer qualify. During the COVID-19 pandemic, the federal government enacted the Families First Coronavirus Response Act, which required states to maintain Medicaid enrollment for all current members in exchange for enhanced federal matching funds -- the "continuous enrollment" provision. This provision prevented states from disenrolling anyone from Medicaid from March 2020 through March 2023, causing Medicaid enrollment to swell from approximately 71 million beneficiaries in February 2020 to 94 million by March 2023 -- an increase of 23 million members, many of whom would not have remained eligible under normal redetermination rules. When the public health emergency ended and the continuous enrollment provision expired, states were permitted (and eventually required) to resume redeterminations in April 2023. The "unwinding" process of removing ineligible members ran from April 2023 through 2024, with states conducting redeterminations at different speeds based on administrative capacity and policy choices. By mid-2024, approximately 15-20 million Medicaid beneficiaries had been disenrolled, either because they no longer met income requirements (they had gotten better-paying jobs during the labor market recovery) or because of administrative failures (outdated contact information, states not processing paperwork in time, members not responding to requests for documentation). For Centene and Molina, both of which derive 80-90% of revenue from Medicaid managed care, this unwinding created a multi-quarter revenue headwind as premium revenue per enrolled member is fixed by capitation contracts with states. Losing 20% of Medicaid members over 18 months means losing approximately 20% of Medicaid premium revenue, while fixed administrative costs cannot decline proportionally in the same period. The offsetting factor is that the members disenrolled during unwinding are often healthier (working-age adults whose incomes rose above thresholds) and less costly than the members who remain, so MLR may improve even as revenue declines. The redetermination cycle is a recurring feature of Medicaid managed care investing: states periodically tighten eligibility, enrollment falls, then expands again during the next economic downturn.

Pharmacy benefit managers (PBMs) are intermediaries between managed care companies (or self-insured employers), drug manufacturers, and retail pharmacies that manage the prescription drug benefit: negotiating drug prices with manufacturers, designing formularies that determine which drugs are covered and at what cost-sharing tier, operating mail-order pharmacy services for maintenance medications, and processing prescription claims at retail pharmacies. The three largest PBMs -- CVS Caremark (part of CVS Health), Express Scripts (part of Cigna's Evernorth segment), and OptumRx (part of UnitedHealth Group) -- control approximately 80% of U.S. prescription drug processing. The PBM business model generates revenue through several mechanisms: administrative fees charged to plan sponsors (employers, MCOs) for processing claims; spread pricing (retaining a portion of the difference between what the PBM pays a pharmacy and what it charges the plan sponsor); manufacturer rebates (drug manufacturers pay rebates to secure preferred formulary placement, a portion of which PBMs retain rather than passing to plan sponsors); and mail-order pharmacy margins (operating their own dispensing pharmacies at margins unavailable to independent retail pharmacies). The integration of PBMs into managed care companies (CVS's acquisition of Aetna in 2018 for $69 billion, Cigna's acquisition of Express Scripts in 2018 for $67 billion, UnitedHealth's organically built OptumRx) reflects the strategic logic that controlling pharmacy economics allows integrated companies to manage total cost of care more effectively: when the same entity manages medical claims, pharmacy claims, and potentially care delivery, it has complete visibility into total member spend and can coordinate interventions (switching a member from a brand-name drug to a generic, adding medication adherence monitoring for diabetics to reduce hospitalizations) that reduce total cost. Critics argue that PBM consolidation into managed care creates conflicts of interest (the PBM designs formularies that may favor its affiliated insurance plan's profit over member access to appropriate drugs) and reduces transparency in drug pricing. Federal and state legislation targeting PBM practices (rebate transparency rules, spread pricing bans in Medicaid, PBM registration requirements) is ongoing.